Community post

Precisio Biotix Therapeutics has acquired London-based CC Bio. This gives Precisio access to CC Bio's ZEUS lysin platform, a bioinformatics platform highly complementary to Precisio's high-throughput screening, engineering, and AI system for creating novel lysins.